INTRODUCTION
The modern pharmaceutical industry is only about 65 years old, but in that time it has revolutionized the practice of medicine by providing the infectious disease specialist with life-saving drugs, such as sulfonamides, penicillins, cephalosporins, aminoglycosides and quinolones, and others. During the last 50 years, medications produced by the pharmaceutical industry have saved more than 1.5 million lives and $140 billion in the treatment of tuberculosis, poliomyelitis, coronary artery disease, and cerebrovascular disease alone (2) . Diseases once considered killers, such as smallpox, have been eradicated; a patient's average hospital stay has been shortened, and institutional space requirements have been reduced.
The process by which pharmaceutical companies bring such innovative medicines to market requires a period of preclinical testing with animals, three phases of clinical trials, two stages of approval from the Food and Drug Administration (FDA), about 12 years of research, and some $359 million in resources. Even after the FDA approves a drug, a pharmaceutical company may continue research with a fourth phase of clinical trials that will allow the practitioner to derive maximum benefits from the drug.
The drug development process is rigorous, for only 1 of every 6,000 compounds tested has a chance of reaching the market. Development of a compound typically requires more than 7 years from the time the drug is first tested with humans. Before 1967, 823 new, single-entity drugs had been introduced into the U.S. pharmaceutical market. Of these, 502 were discovered in the United States, and American pharmaceutical manufacturers were responsible for developing 437. Between 1967 and 1992, nearly 500 new, single-entity drugs were introduced into the U.S. market (2) .
The investment in time is not the only factor involved. The cost of developing new drug entities has escalated over the past 17 years. In 1976, for example, developing a new drug entity cost $54 million, according to an estimate by the University of Rochester (2) . By 1993, that cost had increased by more than 500% ( Fig. 1) (1) . This estimate takes into account the 12 years now projected for the development of a new pharmaceutical product.
To keep up with the demand for new medicines, U.S. pharmaceutical companies have dramatically increased their investments in research and development (R&D). In 1970, American pharmaceutical firms spent $618.5 million on R&D alone. By 1993, that number rose to $12.6 billion (2). More than half of these R&D allocations were spent on development ( Fig. 2) (2) . In 1993, the Pharmaceutical Manufacturers Association compared the percentages of sales invested in R&D by various U.S. industries. It found that the pharmaceutical industry reinvested a higher percentage of its sales revenues in R&D than did the manufacturing, aerospace, and electronics industries combined (Fig. 3) Broad-scale clinical trials, which include studies that enroll patient populations large enough to provide statistical power, are the hallmark of the phase III program. Ideally, the pharmaceutical manufacturer would like as varied a population as possible, including subjects from several geographic locales, to represent a broad demographic distribution. The population also can include outpatients (if appropriate) and inpatients (from both acute-care and extended-care facilities). Comparisons are made between the investigational drug and standard or alternative treatments for that infection. This program provides results that are considered pivotal for FDA approval of the intended product. Comprehensive statistical analyses of data, in addition to careful and complete reports of safety, are done in the phase III clinical trial program. These analyses are combined with those accumulated from the phase II trials. Depending on the targeted diseases, between 1,000 and 3,000 patients may be enrolled, and the program may take 2 to 3 years to complete.
Phase III studies may be designed to address special situations, such as infections in cancer patients and life-threatening infections. By definition, studies with these special populations are not likely to accrue large numbers of patients. Studies with special populations might, for example, target nursing home residents, in whom infections may be of particular concern. Another type of study might focus on drug interactions in immunocompromised or immunocompetent patients taking a number of other medications.
It is not unusual for the three clinical trial phases to overlap, or even for phase I, II, and III trials to be conducted simultaneously. One occasionally hears the term "phase zero" in connection with investigational drugs. This refers to the preclinical testing program conducted for approval of the IND application.
The NDA. When phase III trials have been completed, the pharmaceutical company will assemble the New Drug Application (NDA). "Assemble" is a key term, because this massive document is put together from the clinical, statistical, and bacteriologic findings of many studies, all integrated to provide the required information in a systematic and logical sequence (see Appendix).
An NDA contains both clinical and preclinical information, the latter having been submitted as part of the IND process, as well as additional information gathered since the IND submission. A summary of the contents of a typical NDA for an antibiotic is provided in the Appendix.
FDA review. After the FDA thoroughly reviews the NDA, the pharmaceutical company may receive a letter of approvability if the data are acceptable. This communication from the FDA initiates a meeting between the FDA and representatives of the manufacturer in order to provide the FDA with samples of promotional materials and advertising that will be used to promote the product and to reach an agreement on the contents of the product's package insert. When agreement is reached, the FDA will issue its approval for the pharmaceutical company to begin marketing the new product.
The package insert. The package insert, which is also called the P.I., is the product's complete prescribing information contained in a compact pamphlet that is packaged with the product for distribution to prescribers and pharmacists. The package insert information also appears adjacent to or as part of advertisements and promotional materials that mention the product's name and its intended use. For some products, the mere mention of the product's name requires the printing of full prescribing information with the advertisement. The labelling of some products contains a "black box" warning that alerts the prescriber to a significant toxic or adverse effect(s) that may occur when the drug is used.
Marketing and phase IV studies. The pharmaceutical company continues to conduct clinical studies, even after marketing has begun. These phase IV trials are designed to enhance the efficacy and safety database for the product, to generate reports that can become part of the medical literature, and to compare the product with competitors. The drug's use in phase IV trials is restricted to indications and dosages detailed in the package insert. In enhancing the product's database, postmarketing studies may be used to refine existing dosage forms, to develop new dosage forms, and to evaluate potential interactions with other drugs, foods, and the results of certain laboratory tests.
CONCLUSION
An ethical pharmaceutical company invests a great deal of human effort and financial resources into bringing an antibiotic drug to the marketplace. The clinical investigators and industry personnel expend tremendous effort in this type of endeavor because they believe new antibiotics can eradicate infectious diseases that incapacitate, maim, and kill. Once a drug is marketed, a company's efforts to achieve maximum benefit from that product do not stop. Ongoing studies explore the possibility of new indications and in today's climate, also look at evaluating quality of life and financial outcomes. They may specifically define new therapeutic timed regimens to fit within a cost containment environment, by shortening length of stay and length of treatment for a particular disease or allowing total outpatient treatment for a patient who previously required extensive hospitalization. VOL. 38, 1994 
